RU2012110580A - Способы скрининга in vivo - Google Patents
Способы скрининга in vivo Download PDFInfo
- Publication number
- RU2012110580A RU2012110580A RU2012110580/15A RU2012110580A RU2012110580A RU 2012110580 A RU2012110580 A RU 2012110580A RU 2012110580/15 A RU2012110580/15 A RU 2012110580/15A RU 2012110580 A RU2012110580 A RU 2012110580A RU 2012110580 A RU2012110580 A RU 2012110580A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- dose
- antibody
- administered
- fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
- A61K49/0047—Green fluorescent protein [GFP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
1. Способ лечения фиброза у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг, ослабляющее симптомы фиброза.2. Способ по п.1, в котором фиброз представляет собой фиброз печени или фиброз легких.3. Способ по п.2, который вызывает снижение перекрестного сшивания коллагена, экспрессии гладкомышечного α-актина клетками стромы или числа лейкоцитов в легких у субъекта.4. Способ лечения артрита у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг ослабляющее симптомы артрита.5. Способ лечения опухоли у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг, ослабляющее симптомы опухоли,где опухоль выбрана из группы, состоящей из опухолей молочной железы, поджелудочной железы и яичников.6. Способ по п.5, который вызывает уменьшение среднего объема опухоли или десмоплазии у субъекта.7. Способ по п.5, дополнительно включающий введение субъекту антинео-пластического или химиотерапевтического средства.8. Способ по п.7, в котором средство выбрано из группы, состоящей из таксотера, таксола, сорафениба, гемзара и 5-фторурацила.9. Способ по п.1, в котором антитело вводится два раза в неделю.10. Способ по п.1, в котором антитело вводится в дозе около 1 мг/кг.11. Способ по п.1, в котором антитело вводится в дозе около 3 мг/кг.12. Способ по п.1, в котором антитело вводится в дозе около 5 мг/кг.13. Способ по п.1, в котором антитело вводится в дозе около 15 мг/кг.14. Способ по п.1, в котором антитело вводится в дозе около 30 мг/кг.
Claims (14)
1. Способ лечения фиброза у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг, ослабляющее симптомы фиброза.
2. Способ по п.1, в котором фиброз представляет собой фиброз печени или фиброз легких.
3. Способ по п.2, который вызывает снижение перекрестного сшивания коллагена, экспрессии гладкомышечного α-актина клетками стромы или числа лейкоцитов в легких у субъекта.
4. Способ лечения артрита у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг ослабляющее симптомы артрита.
5. Способ лечения опухоли у субъекта, который включает введение субъекту антитела, специфически связывающегося с LOXL2, в дозе 1, 3, 5, 15 или 30 мг/кг, ослабляющее симптомы опухоли,
где опухоль выбрана из группы, состоящей из опухолей молочной железы, поджелудочной железы и яичников.
6. Способ по п.5, который вызывает уменьшение среднего объема опухоли или десмоплазии у субъекта.
7. Способ по п.5, дополнительно включающий введение субъекту антинео-пластического или химиотерапевтического средства.
8. Способ по п.7, в котором средство выбрано из группы, состоящей из таксотера, таксола, сорафениба, гемзара и 5-фторурацила.
9. Способ по п.1, в котором антитело вводится два раза в неделю.
10. Способ по п.1, в котором антитело вводится в дозе около 1 мг/кг.
11. Способ по п.1, в котором антитело вводится в дозе около 3 мг/кг.
12. Способ по п.1, в котором антитело вводится в дозе около 5 мг/кг.
13. Способ по п.1, в котором антитело вводится в дозе около 15 мг/кг.
14. Способ по п.1, в котором антитело вводится в дозе около 30 мг/кг.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23584609P | 2009-08-21 | 2009-08-21 | |
| US61/235,846 | 2009-08-21 | ||
| PCT/US2010/046196 WO2011022670A1 (en) | 2009-08-21 | 2010-08-20 | In vivo screening assays |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012110580A true RU2012110580A (ru) | 2013-09-27 |
Family
ID=43605534
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012110580/15A RU2012110580A (ru) | 2009-08-21 | 2010-08-20 | Способы скрининга in vivo |
| RU2015124151/15A RU2015124151A (ru) | 2009-08-21 | 2010-08-20 | Способы и композиции для лечения фиброзных заболеваний легких |
| RU2012110578/15A RU2561672C2 (ru) | 2009-08-21 | 2010-08-20 | Способы и композиции для лечения фиброзных заболеваний легких |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015124151/15A RU2015124151A (ru) | 2009-08-21 | 2010-08-20 | Способы и композиции для лечения фиброзных заболеваний легких |
| RU2012110578/15A RU2561672C2 (ru) | 2009-08-21 | 2010-08-20 | Способы и композиции для лечения фиброзных заболеваний легких |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110044981A1 (ru) |
| EP (2) | EP2470218A4 (ru) |
| JP (3) | JP2013502435A (ru) |
| KR (2) | KR20120089274A (ru) |
| CN (2) | CN102711839A (ru) |
| AU (2) | AU2010284039A1 (ru) |
| BR (2) | BR112012008111A2 (ru) |
| CA (2) | CA2771786A1 (ru) |
| IL (2) | IL218211A0 (ru) |
| MX (2) | MX2012002270A (ru) |
| NZ (2) | NZ598464A (ru) |
| RU (3) | RU2012110580A (ru) |
| SG (1) | SG178846A1 (ru) |
| WO (1) | WO2011022706A2 (ru) |
| ZA (1) | ZA201201290B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| DK2185198T3 (en) * | 2007-08-02 | 2015-04-20 | Gilead Biologics Inc | LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| SG2014004816A (en) * | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| CN102711821A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗方法和组合物 |
| JP2013506005A (ja) * | 2009-09-29 | 2013-02-21 | ギリアド バイオロジクス，インク． | 眼の繊維症の処置のための方法及び組成物 |
| SG183174A1 (en) * | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
| TW201319572A (zh) * | 2011-06-01 | 2013-05-16 | Gilead Biologics Inc | 類氨醯氧化酶樣2(lysyl oxidase-like 2)測定及其使用方法 |
| CN107982531A (zh) * | 2012-10-30 | 2018-05-04 | 吉利德科学公司 | 与赖氨酰氧化酶样蛋白2 (loxl2)相关的治疗和诊断方法 |
| HK1219533A1 (zh) * | 2013-03-15 | 2017-04-07 | Intermune, Inc. | 蛋白质组学ipf标志物 |
| WO2017152062A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| EP3644983B1 (en) | 2017-06-29 | 2023-10-25 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| EP3765059A4 (en) * | 2018-03-12 | 2022-01-12 | Yale University | METHODS OF TREATMENT OR PREVENTION OF ACUTE RESPIRATORY SYNDROME |
| CN110917351A (zh) * | 2018-09-20 | 2020-03-27 | 华中科技大学同济医学院附属同济医院 | Mbd2抑制剂在预防和治疗纤维化疾病中的用途 |
| CN112138159B (zh) * | 2019-06-28 | 2022-07-12 | 复旦大学 | 乳酸脱氢酶在组织炎症和纤维化治疗中的应用 |
| WO2021015218A1 (ja) * | 2019-07-24 | 2021-01-28 | 国立大学法人九州大学 | 転写関連因子を標的とする線維化疾患の予防または治療 |
| US20220288004A1 (en) * | 2019-09-23 | 2022-09-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Treatment and prevention of aging related-disease and/or aging by the inhibition of sphingolipids |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3901654A (en) * | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3867517A (en) * | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US4034074A (en) * | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS57501234A (ru) * | 1980-08-25 | 1982-07-15 | ||
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) * | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| ATE45735T1 (de) * | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4627445A (en) * | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
| US4801531A (en) * | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4943593A (en) * | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) * | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) * | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5120764A (en) * | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5192659A (en) * | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US6235887B1 (en) * | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5281521A (en) * | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6015562A (en) * | 1992-09-22 | 2000-01-18 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5721138A (en) * | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
| CZ292465B6 (cs) * | 1996-02-09 | 2003-09-17 | Abbott Laboratories (Bermuda) Ltd. | Lidské protilátky k lidskému TNFalfa |
| DE69809391T2 (de) * | 1997-02-06 | 2003-07-10 | Therasense, Inc. | Kleinvolumiger sensor zur in-vitro bestimmung |
| DE69840113D1 (de) * | 1997-08-08 | 2008-11-20 | Univ California | Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern |
| US6277622B1 (en) * | 1997-08-11 | 2001-08-21 | The University Of Sydney | Synthetic polynucleotides |
| US6225118B1 (en) * | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
| CA2308565A1 (en) * | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| US20020072089A1 (en) * | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| US6140056A (en) * | 1999-01-27 | 2000-10-31 | Millennium Pharmaceuticals, Inc. | MSP-18 protein and nucleic acid molecules and uses therefor |
| US6300092B1 (en) * | 1999-01-27 | 2001-10-09 | Millennium Pharmaceuticals Inc. | Methods of use of a novel lysyl oxidase-related protein |
| US20040058355A1 (en) * | 1998-09-30 | 2004-03-25 | Millennium Pharmaceuticals, Inc. | Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor |
| US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US20030149997A1 (en) * | 1999-02-19 | 2003-08-07 | Hageman Gregory S. | Diagnostics and therapeutics for arterial wall disruptive disorders |
| US20030152926A1 (en) * | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| GB0001309D0 (en) * | 2000-01-20 | 2000-03-08 | Nestle Sa | Valve arrangement |
| CA2405781A1 (en) * | 2000-04-14 | 2001-10-25 | Incyte Genomics, Inc. | Secreted proteins |
| US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| GB0014185D0 (en) * | 2000-06-09 | 2000-08-02 | Novartis Res Found | Compound and method |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| DE60128830T2 (de) * | 2000-08-08 | 2008-01-31 | Wyeth | Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren |
| AU2002241520A1 (en) * | 2000-11-28 | 2003-03-03 | University Of Cincinnati | Blood assessment of injury |
| US20040029114A1 (en) * | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| US20020182274A1 (en) * | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| US20030092037A1 (en) * | 2001-07-18 | 2003-05-15 | Osamu Matsuzaki | Elk1 phosphorylation related gene |
| US20030129672A1 (en) * | 2001-08-29 | 2003-07-10 | Dyer Richard Dennis | Method for identifying metalloenzyme inhibitors |
| CN1608133A (zh) * | 2001-10-26 | 2005-04-20 | 里伯药品公司 | 双链核糖核酸用于治疗正(+)链rna病毒感染的用途 |
| KR100450950B1 (ko) * | 2001-11-29 | 2004-10-02 | 삼성전자주식회사 | 구내/공중망 무선 패킷데이터 서비스를 받는 이동단말기의 인증 방법 및 그 사설망 시스템 |
| WO2003051388A2 (en) * | 2001-12-18 | 2003-06-26 | Mondobiotech Laboratories Anstalt | Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| US7186540B2 (en) * | 2001-12-27 | 2007-03-06 | National Institute of Advanced Indusrtial Science and Technology | Thermostable glutaminase and thermostable glutaminase gene |
| CN1653080A (zh) * | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | 淋巴管和血管的内皮细胞基因 |
| US7655397B2 (en) * | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| AU2003263760A1 (en) * | 2002-06-27 | 2004-01-19 | The General Hospital Corporation | Methods for the treatment or prevention of obesity |
| JP2006512924A (ja) * | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | 脳内皮細胞発現パターン |
| US20050020521A1 (en) * | 2002-09-25 | 2005-01-27 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable siRNA |
| US20040156854A1 (en) * | 2002-12-06 | 2004-08-12 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| WO2004078124A2 (en) * | 2003-03-03 | 2004-09-16 | Board Of Regents, The University Of Texas System | Methods and compositions involving mda-7 |
| US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005010213A2 (en) * | 2003-07-17 | 2005-02-03 | Pacific Edge Biotechnology, Ltd. | Markers for detection of gastric cancer |
| WO2005025596A1 (en) * | 2003-09-16 | 2005-03-24 | Hadasit Medical Research Services & Development Ltd. | Glatiramer acetate for use as an immuno-modulatory agent |
| US20070054278A1 (en) * | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| EP1706139A4 (en) * | 2004-01-23 | 2009-06-17 | Massachusetts Eye & Ear Infirm | LYSYL OXIDASE-LIKE 1 (LOXL1) AND ELASTOGENESIS |
| WO2005083107A2 (en) * | 2004-02-24 | 2005-09-09 | Attenuon Llp | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| US20060134172A1 (en) * | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| CA2599004C (en) * | 2005-02-28 | 2015-05-26 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
| US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| US20090035348A1 (en) * | 2005-11-22 | 2009-02-05 | Z & Z Medical Holdings, Inc. | Dissolution of arterial plaque |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| ES2525325T3 (es) * | 2005-12-09 | 2014-12-22 | Ucb Pharma S.A. | Moléculas de anticuerpo que tienen especificidad por la IL-6 humana |
| US8077896B2 (en) * | 2006-12-12 | 2011-12-13 | Sound Services, Llc | Laser inclinometer audio direction |
| WO2008144720A2 (en) * | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
| WO2009002931A2 (en) * | 2007-06-22 | 2008-12-31 | Children's Medical Center Corporation | Methods and uses thereof of prosaposin |
| IL184627A0 (en) * | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
| DK2185198T3 (en) * | 2007-08-02 | 2015-04-20 | Gilead Biologics Inc | LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF |
| WO2010080769A2 (en) * | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| SG2014004816A (en) * | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
| CN102711821A (zh) * | 2009-08-21 | 2012-10-03 | 吉联亚生物科技有限公司 | 治疗方法和组合物 |
| JP2013506005A (ja) * | 2009-09-29 | 2013-02-21 | ギリアド バイオロジクス，インク． | 眼の繊維症の処置のための方法及び組成物 |
-
2010
- 2010-08-20 EP EP20100810702 patent/EP2470218A4/en not_active Withdrawn
- 2010-08-20 MX MX2012002270A patent/MX2012002270A/es unknown
- 2010-08-20 NZ NZ598464A patent/NZ598464A/en unknown
- 2010-08-20 EP EP10810675A patent/EP2467169A4/en not_active Withdrawn
- 2010-08-20 BR BR112012008111A patent/BR112012008111A2/pt not_active IP Right Cessation
- 2010-08-20 KR KR1020127007162A patent/KR20120089274A/ko not_active Withdrawn
- 2010-08-20 NZ NZ625850A patent/NZ625850A/en not_active IP Right Cessation
- 2010-08-20 AU AU2010284039A patent/AU2010284039A1/en not_active Abandoned
- 2010-08-20 WO PCT/US2010/046244 patent/WO2011022706A2/en not_active Ceased
- 2010-08-20 US US12/860,834 patent/US20110044981A1/en not_active Abandoned
- 2010-08-20 CA CA2771786A patent/CA2771786A1/en not_active Abandoned
- 2010-08-20 KR KR1020127007167A patent/KR20120054077A/ko not_active Ceased
- 2010-08-20 AU AU2010283997A patent/AU2010283997B2/en active Active
- 2010-08-20 CN CN2010800479711A patent/CN102711839A/zh active Pending
- 2010-08-20 RU RU2012110580/15A patent/RU2012110580A/ru unknown
- 2010-08-20 MX MX2012002269A patent/MX2012002269A/es not_active Application Discontinuation
- 2010-08-20 JP JP2012525746A patent/JP2013502435A/ja active Pending
- 2010-08-20 CA CA2771778A patent/CA2771778A1/en not_active Abandoned
- 2010-08-20 SG SG2012012167A patent/SG178846A1/en unknown
- 2010-08-20 RU RU2015124151/15A patent/RU2015124151A/ru not_active Application Discontinuation
- 2010-08-20 BR BR112012008080A patent/BR112012008080A2/pt not_active IP Right Cessation
- 2010-08-20 JP JP2012525736A patent/JP2013502589A/ja not_active Withdrawn
- 2010-08-20 CN CN2010800479707A patent/CN102711820A/zh active Pending
- 2010-08-20 RU RU2012110578/15A patent/RU2561672C2/ru active
-
2012
- 2012-02-20 IL IL218211A patent/IL218211A0/en unknown
- 2012-02-20 IL IL218210A patent/IL218210A0/en unknown
- 2012-02-21 ZA ZA2012/01290A patent/ZA201201290B/en unknown
-
2015
- 2015-10-22 JP JP2015207723A patent/JP2016029085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ625850A (en) | 2015-12-24 |
| RU2015124151A (ru) | 2015-12-27 |
| JP2013502589A (ja) | 2013-01-24 |
| EP2470218A4 (en) | 2013-04-03 |
| IL218211A0 (en) | 2012-04-30 |
| IL218210A0 (en) | 2012-04-30 |
| ZA201201290B (en) | 2014-01-29 |
| JP2016029085A (ja) | 2016-03-03 |
| EP2467169A1 (en) | 2012-06-27 |
| BR112012008111A2 (pt) | 2017-02-21 |
| CA2771778A1 (en) | 2011-02-24 |
| WO2011022706A2 (en) | 2011-02-24 |
| BR112012008080A2 (pt) | 2017-07-04 |
| CA2771786A1 (en) | 2011-02-24 |
| CN102711820A (zh) | 2012-10-03 |
| WO2011022706A3 (en) | 2011-04-14 |
| EP2470218A2 (en) | 2012-07-04 |
| KR20120089274A (ko) | 2012-08-09 |
| NZ598464A (en) | 2014-07-25 |
| US20110044981A1 (en) | 2011-02-24 |
| AU2010284039A1 (en) | 2012-03-22 |
| AU2010283997B2 (en) | 2015-04-09 |
| AU2010283997A1 (en) | 2012-03-22 |
| SG178846A1 (en) | 2012-04-27 |
| RU2561672C2 (ru) | 2015-08-27 |
| RU2012110578A (ru) | 2013-09-27 |
| JP2013502435A (ja) | 2013-01-24 |
| CN102711839A (zh) | 2012-10-03 |
| EP2467169A4 (en) | 2013-01-02 |
| MX2012002270A (es) | 2012-07-20 |
| KR20120054077A (ko) | 2012-05-29 |
| MX2012002269A (es) | 2012-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012110580A (ru) | Способы скрининга in vivo | |
| Lane et al. | Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial–mesenchymal transition | |
| JP2021063120A5 (ru) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| RU2012111235A (ru) | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог | |
| JP2013509429A5 (ru) | ||
| JP2016533366A5 (ru) | ||
| JP2008507530A5 (ru) | ||
| FI2547205T3 (fi) | Uusia menetelmiä syövän kantasolujen kohdentamiseksi | |
| JP2010001302A5 (ru) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| ME02806B (me) | Protutijela protiv csf-1r | |
| JP2014526450A5 (ru) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| JP2016503414A5 (ru) | ||
| UA107675C2 (xx) | Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом | |
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| JP2014503593A5 (ru) | ||
| JP2014523398A5 (ru) | ||
| SG171674A1 (en) | Methods of treating cancer by administering human il-18 combinations | |
| JP2014530181A5 (ru) | ||
| JP2013528215A5 (ru) | ||
| JP2014500871A5 (ru) | ||
| Zhang et al. | Blocking endogenous H2S signaling attenuated radiation-induced long-term metastasis of residual HepG2 cells through inhibition of EMT |